Rita Cortvrindt

Business Developer at the Department of Internal Medicine and Pediatrics (Faculty of Medicine and Health Sciences, UGent)


With our successful Immuno-T project , a motion comic explaining in an easy and engaging way how immunotherapy works,  we now aim to extend this and establish the Cancer-T.inmotion.care platform. 
Cancer -T. inmotion.care  will be a sustainable platform,  to increase the quality of life and empowerment of cancer patients and encourage an open communication on cancer within  the community.  
We aim to accomplish this by providing  up-to-date scientifically sound information and support by means of innovative digital tools.  
The digital tools can be motion comics,  to visualise these different complex processes,  augmented or virtual reality applications to present and clarify diverse situations, or games to mimic and experience emotions.  These tools will be useful for professional caregivers, to explain the complex processes of cancer development, treatment and follow-up care to patients and their informal carers.
We invite all stakeholders to contribute with their specific resources to support our project, aiming to co-create and maintain the Cancer-T.inmotion.care platform for the benefit of the whole cancer community.  


Rita Cortvrindt, graduated as Master in Science / Biology at the University of Ghent in 1983 and obtained the degree of Master in Medical and Pharmaceutical Research at the Free University of Brussels in 1989. In the meantime she worked as research assistant at the University of Antwerp in the departments of Pathology (Cancer Research) and Biochemistry (In vitro bone development).   In 1994 she joined the Centre for reproductive medicine of Brussels, to set up and coordinate the Follicle Biology group, focussing on the in vitro growth, maturation and cryopreservation of oocytes.  Based on that work she co-founded in 2002 the spinoff company EggCentris, a CRO focussed on the safeguarding of reproductive health, offering services to the pharmaceutical, chemical, cosmetic and medical device industry, which she managed until 2014.   
The last 20 years she gained a profound expertise in (in vitro) toxicology and is an European Registered Toxicologist (ERT). Furthermore she developed skills in quality assurance (BELAC auditor) and business development. 

Research team

Key publications

  • First childbirth from transplanted cryopreserved ovarian tissue brings hope for cancer survivors. Smitz J, Cortvrindt R.  Lancet. (2004)  PMID:15488198
  • Follicle culture after ovarian cryostorage.  Smitz J, Cortvrindt R.  Maturitas. (1998) PMID: 9871910
  • Smitz J and Cortvrindt R (1998).  Preservation of gonadal function after cancer therapy in women. Smitz J and Cortvrindt R (1998).   In Proceedings of the IVth Sapporo Meeting, August 1-3, Sapporo, Japan.  Editor: Seiichiro Fujimoto, Hokkaido University, Japan; Publisher: Ares Serono Foundation.
  • Cryopreservation of ovaries before cancer therapy.  Smitz J and Cortvrindt R (1998).  Int J Fertil 43 (4), 202-203.
  • 5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma. Cortvrindt R, Bernheim J, Buyssens N, Roobol K.   Br J Cancer. (1987)  PMID: 2444244 

Contact & links

  • Lab address: Corneel Heymanslaan 10, 9000 Ghent
  • Immuno-T 
  • Google Scholar 
  • Rita Cortvrindt is interested to receive invitations for presentations or talks